The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli

Haggarty and colleagues situate this study within evidence that acute 3,4-methylenedioxymethamphetamine (MDMA) increases sociability, empathy and social perception on self-report and behavioural measures, while reducing social anxiety and sensitivity to negative emotions. Previous work has proposed that MDMA's prosocial effects may involve serotonin and oxytocin systems, but the neural mechanisms mediating enhanced social processing are not fully characterised. Event-related potentials (ERPs) elicited by emotional faces—particularly the N170 (face structural encoding), P300 (attention allocation) and mismatch negativity (MMN; novelty detection)—provide a means to examine early visual and socio-emotional processing and how it is altered by psychoactive drugs. This study tested whether MDMA selectively enhances early visual processing of socio-emotional stimuli compared with a prototypic stimulant, methamphetamine (MA), and placebo. Using a double-blind, within-participant design, the investigators administered MDMA (100 mg), MA (20 mg) and placebo in separate sessions and recorded EEG during an emotional oddball faces task. The primary hypothesis was that MDMA, but not MA, would increase N170 and possibly P300 amplitudes for emotionally salient faces, indicating enhanced early processing of social cues. The work aims to clarify whether MDMA's neural effects on social processing differ from those of a standard stimulant and to inform considerations for therapeutic applications of MDMA-assisted interventions.

The study employed a double-blind, within-participant design. Healthy adults (N = 25; 17 men, 8 women; mean age 27.4 years) who reported 4–40 prior MDMA experiences were recruited. Key inclusion criteria included fluency in English, BMI 18–26 and general good health; exclusion criteria included prescription medication use, cardiac disease or high blood pressure and previous negative experiences with MDMA or hallucinogens. Women not using oral contraceptives were tested during the follicular menstrual phase. Sessions were separated by at least 4 days (mean = 7.5 days). Participants completed three 4-hour drug sessions (09:00–13:00) in which they received, under double-blind conditions, capsules containing MDMA 100 mg (powdered MDMA), methamphetamine (MA) 20 mg (tablets), or placebo (dextrose). Urine and breath tests screened for recent drug or alcohol use, and pregnancy tests were performed for female participants. EEG electrodes were placed ~30 minutes after capsule ingestion and recording began ~60 minutes post-capsule; EEG measures for the reported task were obtained between 60 and 150 minutes after dosing. After EEG recordings, participants completed valence and arousal ratings for the faces they had seen. EEG was recorded with a 64-channel electro-geodesic net, sampled at 1024 Hz (down-sampled to 512 Hz offline), high-pass filtered at 1 Hz and low-pass filtered at 60 Hz. Independent component analysis was used to remove artefacts (blinks, eye movements, muscle, EKG). Data were segmented from −200 to 1000 ms relative to stimulus onset and baseline corrected; segments with remaining ±100 μV were rejected. A threshold of >80% good segments was required for inclusion; all participants met this threshold. The behavioural task was an emotional oddball paradigm with 300 stimuli (80% frequent cartoon faces, 20% infrequent human faces). Infrequent human faces were presented in separate blocks by emotion (happy, angry, neutral) to permit valence-specific analysis. Participants indicated whether a stimulus was a human or cartoon face via button press. Primary ERP outcomes were: N170 measured at PO8 (mean peak 150–200 ms), P300 at Pz (mean peak 300–400 ms) and MMN at Fz (240–350 ms). Analyses compared each drug to placebo separately using repeated-measures ANOVAs with factors for emotion (three levels) and drug condition. Self-report measures included the Drug Effects Questionnaire and visual analogue scales for friendliness/sociability; face valence/arousal ratings used a −4 to +4 Likert scale. Peak change from baseline and paired t-tests were used for subjective measures.

Demographics and blinding: The sample comprised 17 men and 8 women (mean age 27.4 years) with a mean of 7.1 prior MDMA uses. On the session-end questionnaire, 64% of participants correctly identified placebo, 20% correctly identified MA and 52% correctly identified MDMA, indicating partial success of blinding. Subjective effects: Both MDMA and MA increased ‘‘Feel Drug’’ ratings relative to placebo (MDMA: t(24) = 7.83, p < .001; MA: t(24) = −2.03, p = .05). MDMA increased ‘‘liking’’ compared with placebo (t(24) = −3.93, p = .001) while MA did not reach conventional significance for liking (t(24) = −2.00, p = .06). Both drugs increased ‘‘wanting more’’ (MDMA: t(24) = −3.32, p = .003; MA: t(24) = −2.38, p = .03). On VAS measures, MDMA increased feelings of friendliness (t(23) = −2.06, p = .05); MA increased both friendliness (t(23) = −2.15, p = .04) and sociability (t(24) = −2.14, p = .04). End-of-session liking means were higher for MDMA (mean = 78.0) and MA (mean = 71.2) than placebo (mean = 48.2). Face ratings and behavioural performance: Participants rated happy faces as more positive and angry faces as more negative than neutral faces, as expected. Neither MDMA nor MA altered these valence or arousal ratings according to the extracted text. ERP findings — N170: The principal neurophysiological finding was that MDMA significantly increased N170 peak amplitude at PO8 for emotional faces, specifically for happy and angry faces compared with neutral faces. Reported means were: for happy faces MDMA M = −2.27 μV versus placebo M = −1.04 μV; for angry faces MDMA M = −2.09 μV versus placebo M = −1.31 μV. The drug × emotion interaction for MDMA versus placebo was significant (F[2,86] = 4.49, p = .01, ηp2 = .10). There was also a main effect of emotion across MDMA and placebo (F[2,88] = 7.86, p = .001, ηp2 = .15). In contrast, MA did not affect N170 amplitude relative to placebo (drug × emotion interaction F[2,86] = 0.31, p > .05, ηp2 = .007), and in the MA versus placebo analysis emotion did not show a significant main effect (F[2,86] = 1.21, p > .05, ηp2 = .03). ERP findings — P300 and MMN: Neither MDMA nor MA produced significant changes in P300 amplitude relative to placebo; the P300 was smaller for cartoon than human faces but was not modulated by emotion or drug in the reported analyses. The MMN, measured at Fz, was greater for infrequent human faces than for frequent cartoon faces, consistent with novelty sensitivity, but neither drug altered MMN amplitude for emotional faces. Initial analyses indicated responses to frequent cartoon faces differed markedly from infrequent human faces across ERP measures; final reported ERP analyses therefore focused on human faces and compared each drug separately to placebo.

Haggarty and colleagues interpret their results as evidence that MDMA selectively enhances early visual processing of socio-emotional stimuli, as indexed by increased N170 amplitude for happy and angry faces. They propose that this potentiation of the N170 reflects augmented structural encoding of emotionally salient faces and may occur prior to effects on later cognitive processes. The absence of MDMA effects on P300 and MMN suggests the drug did not broadly alter attention allocation or novelty detection in this task, so the effect appears relatively specific to early face-sensitive visual processing. The authors relate the N170 finding to prior observations that oxytocin can enhance N170 responses to faces, noting that MDMA's prosocial effects have been linked to oxytocin and serotonergic systems; the parallel is presented as consistent with the idea that enhanced early face processing could support social approach or avoidance behaviours. They also contrast MDMA with MA, noting MA did not modulate N170 and therefore MDMA may differ from prototypic stimulants in its effects on social processing. Several limitations are acknowledged. The sample was homogeneous (healthy adults aged 18–35 with prior MDMA use) and modest in size, which may limit generalisability and sensitivity to subtle effects. Only single doses of MDMA (100 mg) and MA (20 mg) were tested, and the MA dose may not be potency-matched to MDMA across relevant transporter targets; dose–response studies would be needed. The inter-session washout of at least 4 days (mean 7.5 days) was shorter than the five half-lives often used in pharmaceutical trials and may not guarantee full neurochemical recovery, particularly for serotonergic systems. Task limitations are also noted: the emotional oddball paradigm used cartoon faces as frequent stimuli and segregated emotions by block, which may influence sensitivity to some effects; more ecologically valid or complex social tasks could reveal additional drug effects. In terms of implications, the investigators suggest that MDMA's enhancement of early neural responses to facial emotion cues could contribute to therapeutic mechanisms in MDMA-assisted psychotherapy by increasing attention to and processing of interpersonal emotional signals, potentially strengthening therapeutic alliance and emotional engagement. They call for further studies to clarify valence-specific effects, dose dependencies, longer inter-session intervals, and how these neural changes relate to behavioural and clinical outcomes.